Skip to main
BNTX

BioNTech SE (BNTX) Stock Forecast & Price Target

BioNTech SE (BNTX) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 27%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

BioNTech concluded the third quarter of 2025 with approximately €16.7 billion in cash, cash equivalents, marketable securities, and trade receivables, providing the company with substantial financial flexibility to support its research and development initiatives. The progress of its oncology pipeline, especially the upcoming global Phase 3 DYNASTY-Breast02 trial for BNT323, indicates a positive trajectory for its cancer therapeutics segment. Additionally, the improvements in immune responses demonstrated by its adapted COVID-19 vaccine highlight BioNTech's commitment to innovation in both oncology and infectious disease therapies, underscoring the company's potential for sustained growth.

Bears say

BioNTech faces significant risks that contribute to a negative outlook, including the possibility of negative clinical data across multiple oncology candidates, which could hinder their market acceptance and development timelines. The projected full-year net loss per diluted share of €3.99 for 2025, coupled with an already recorded net loss of €0.12 per diluted share for 3Q25, indicates ongoing financial challenges that may deter investor confidence. Furthermore, changing dynamics in the COVID-19 vaccine market, particularly with increased regulatory scrutiny in the U.S., may overshadow the company's oncology portfolio and further complicate its financial recovery.

BioNTech SE (BNTX) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 27% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioNTech SE (BNTX) Forecast

Analysts have given BioNTech SE (BNTX) a Buy based on their latest research and market trends.

According to 11 analysts, BioNTech SE (BNTX) has a Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $137.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $137.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioNTech SE (BNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.